Patent Judgment Threatens Guardant Health's Dominance in Cancer Testing The recent patent judgment against Guardant Health, Inc.
has left investors reeling, but a closer look at the ruling reveals that it may not be as dire as initially thought.
The $245 million award is significant, but the company's decision to update its technology and exclude current versions of certain products from the order suggests a more nuanced picture.